Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

Please provide your email address to receive an email when new articles are posted on . Patients treated with tumor necrosis factor inhibitors experienced a shorter time until cancer progression.

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.

Researchers at University of Texas Release New Data on Rheumatoid Arthritis (Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Since 2008, there has been no “consistent increase” in ...

Relapse occurred in over half of patients with juvenile idiopathic arthritis (JIA) within a year of stopping biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) treatment after ...

Patients who require biologic disease-modifying antirheumatic drugs (DMARDs) for severe RA are less likely to achieve sustained DMARD-free remission than those not needing the medication. Patients ...

RA RA patients treated with biologics have exhibited either clinical remission or low disease activity on follow-up visits. Most patients diagnosed with rheumatoid arthritis (RA) and treated with ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...